Oral symptoms of patients tested positive for COVID-19 with mild severity- a cross-sectional study

Authors

  • Fatemeh Tavakoli Graduate student, Oral and Maxillofacial Disease Department, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
  • Fatemeh Lavaee DMD, Associate Professor of Oral and Dental Disease Research Center, Oral and Maxillofacial Disease Department, School of Dentistry, Shiraz University of Medical Sciences, Ghasrdasht street, Shiraz, Iran
  • Maryam TazarviFardShirazi Graduate student, Oral and Maxillofacial Disease Department, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
  • Shirin Fattahi Assistant Professor, Department of Pathology, School of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran

DOI:

https://doi.org/10.5195/d3000.2022.375

Keywords:

COVID-19, Recurrent Herpes, Xerostomia

Abstract

BACKGROUND: The pandemic of Coronavirus disease (COVID-19) has a major effect on the world. It has several signs and symptoms and the cause of some oral lesions may be related to this virus.

OBJECTIVES: The aim of the study is to determine the proportion, and evaluate the different oral symptoms and their time of presentation in patients with mild COVID -19 infection

MATERIALS AND METHODS: The present study included 55 participants (40%) females and (60%) males, with an average age of 38.52 ± 10.46 years. 

RESULTS: About 80% (43 patients) had oral symptoms such as Xerostomia, Recurrent Herpes simples, aphthous stomatitis, gingival pain, or other symptoms.

Conclusion: COVID-19 has been shown to have some effects on the mouth because a large proportion of COVID-19 patients had oral symptoms.

CLINICAL SIGNIFICANCE: This research showed a high percentage of COVID-19 patients experienced dry mouth, after that the most likely lesions were Herpes; also, other lesions may occur. In addition, dentists should be conscious of oral manifestation, particularly during the Coronavirus pandemic.

References

Laboratory diagnosis of emerging human coronavirus infections–the state of the art. Emerging microbes & infections. Loeffelholz MJ, Tang Y-W. 2020;9(1):747-56.

Cutaneous manifestations and considerations in COVID‐19 pandemic: a systematic review. Dermatologic therapy. Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, et al. 2020;33(6):e13986.

Management of Undifferentiated Critically Ill COVID-19 Patients. Critical Care of COVID-19 in the Emergency Department: Springer; Tran QK. 2021. p. 11-7.

Clinical characteristics of coronavirus disease 2019 in China. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. New England journal of medicine. 2020;382(18):1708-20.

The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms. McLachlan CS. Clinical hypertension. 2020;26(1):1-3.

Review on the oral manifestations of Covid-19 disease and Mucormycosis. Negi P, Kumari P, Negi S. Journal of Advanced Medical and Dental Sciences Research. 2021;9(6):64-7.

Imaging diagnostics and pathology in SARS-CoV-2-related diseases. Scimeca M, Urbano N, Bonfiglio R, Montanaro M, Bonanno E, Schillaci O, et al. International Journal of Molecular Sciences. 2020;21(18):6960.

Oral manifestations in patients with COVID-19: a living systematic review. Amorim Dos Santos J, Normando A, Carvalho da Silva R, Acevedo A, De Luca Canto G, Sugaya N, et al. Journal of dental research. 2021;100(2):141-54.

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. Hamming I, Timens W, Bulthuis M, Lely A, Navis Gv, van Goor H. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2004;203(2):631-7.

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. The Lancet respiratory medicine. 2020;8(4):420-2.

Extensive hard palate hyperpigmentation associated with chloroquine use. Godinho GV, Paz ALLM, de Araújo Gomes EPA, Garcia CL, Volpato LER. British journal of clinical pharmacology. 2020;86(11):2325-7.

A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). Rameshrad M, Ghafoori M, Mohammadpour AH, Nayeri MJD, Hosseinzadeh H. Naunyn-Schmiedeberg's archives of pharmacology. 2020;393(7):1137-52.

COVID-19: symptoms and severity [Internet]. 18 April 2022.

Co-infections: potentially lethal and unexplored in COVID-19. Cox MJ, Loman N, Bogaert D, O'Grady J. The Lancet Microbe. 2020;1(1):e11.

50 years on. La Clinica Terapeutica. Petrini C. Helsinki 2014;165(4):179-81.

A new coronavirus associated with human respiratory disease in China. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. Nature. 2020;579(7798):265-9.

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. The lancet. 2020;395(10223):507-13.

Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Journal of preventive medicine and hygiene. 2020;61(3):E304.

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. The Lancet Respiratory Medicine. 2020;8(5):475-81.

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. Military Medical Research. 2020;7(1):1-10.

World meters. available from: https://wwwworldometersinfo/coronavirus/#countries.

Investigation of COVID-19-related symptoms based on factor analysis. Luo Y, Wu J, Lu J, Xu X, Long W, Yan G, et al. Ann Palliat Med. 2020;9(4):1851-8.

The impact of coronavirus infectious disease 19 (COVID‐19) on oral health. Dziedzic A, Wojtyczka R. Oral diseases. 2021;27:703-6.

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. The Journal of infectious diseases. 2020;221(11):1762-9.

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Tufan A, Güler AA, Matucci-Cerinic M. Turkish journal of medical sciences. 2020;50(SI-1):620-32.

The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. McGonagle D, Sharif K, O'Regan A, Bridgewood C. Autoimmunity reviews. 2020;19(6):102537.

COVID-19 and the immune system. Paces J, Strizova Z, Daniel S, Cerny J. Physiological research. 2020;69(3):379.

SARS‐CoV‐2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. Current protocols in microbiology. 2020;57(1):e100.

Immune response in COVID-19: A review. Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Journal of infection and public health. 2020;13(11):1619-29.

Covid-19 symptomatic patients with oral lesions: clinical and histopathological study on 123 cases of the university hospital policlinic of bari with a purpose of a new classification. Favia G, Tempesta A, Barile G, Brienza N, Capodiferro S, Vestito MC, et al. Journal of Clinical Medicine. 2021;10(4):757.

Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: an international multicenter study. Qiu C, Cui C, Hautefort C, Haehner A, Zhao J, Yao Q, et al. Otolaryngology–Head and Neck Surgery. 2020;163(4):714-21.

Oral Manifestations of COVID-19 Infection: An Analytical Cross-Sectional Study. Ganesan A, Kumar S, Kaur A, Chaudhry K, Kumar P, Dutt N, et al. Journal of maxillofacial and oral surgery. 2022:1-10.

Oral manifestations of COVID‐19 disease: A review article. Iranmanesh B, Khalili M, Amiri R, Zartab H, Aflatoonian M. Dermatologic therapy. 2021;34(1):e14578.

Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19? Sakaida T, Tanimoto I, Matsubara A, Nakamura M, Morita A. Journal of dermatological science. 2020;99(1):62-4.

Oral vesiculobullous lesions associated with SARS‐CoV‐2 infection. Carreras‐Presas CM, Sánchez JA, López‐Sánchez AF, Jané‐Salas E, Pérez MLS. Oral diseases. 2020.

COVID‐19 from the perspective of dentists: a case report and brief review of more than 170 cases. Eghbali Zarch R, Hosseinzadeh P. Dermatologic Therapy. 2021;34(1):e14717.

Oral complications of ICU patients with COVID-19: case-series and review of two hundred ten cases. Hocková B, Riad A, Valky J, Šulajová Z, Stebel A, Slávik R, et al. Journal of clinical medicine. 2021;10(4):581.

The effect of xylitol on dental caries and oral flora. Nayak PA, Nayak UA, Khandelwal V. Clinical, cosmetic and investigational dentistry. 2014;6:89.

Oral mucosal lesions in a COVID-19 patient: New signs or secondary manifestations? Dos Santos JA, Normando AGC, da Silva RLC, De Paula RM, Cembranel AC, Santos-Silva AR, et al. International Journal of Infectious Diseases. 2020;97:326-8.

Downloads

Published

2022-10-14

Issue

Vol. 10 No. 1 (2022)

Section

Adults & the Elderly

License

Authors who publish with this journal agree to the following terms:

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
    with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
  4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
  5. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
  6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
  7. The Author represents and warrants that:
    1. the Work is the Author’s original work;
    2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
    3. the Work is not pending review or under consideration by another publisher;
    4. the Work has not previously been published;
    5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
    6. the Work contains no libel, invasion of privacy, or other unlawful matter.
  8. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Revised 7/16/2018. Revision Description: Removed outdated link.